Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21769252 | 0.96 | TSHR (0.42) | TSHRKDM4ESMN1; SMN2LMNAUSP2 | |
| SCHEMBL21769506 | 0.95 | RBP4 (0.41) | TSHRKDM4ESMN1; SMN2USP2CYP1A2 | |
| SCHEMBL21769410 | 0.95 | TSHR (0.41) | TSHRKDM4ESMN1; SMN2LMNAUSP2 | |
| SCHEMBL21769398 | 0.92 | KDM4E (0.46) | TSHRKDM4ESMN1; SMN2USP2CYP1A2 | |
| SCHEMBL21769247 | 0.90 | TSHR (0.42) | TSHRKDM4ESMN1; SMN2LMNAUSP2 | |
| SCHEMBL21769489 | 0.90 | RBP4 (0.41) | TSHRKDM4ESMN1; SMN2USP2CYP1A2 | |
| SCHEMBL21769505 | 0.90 | CYP1A2 (0.39) | TSHRKDM4ESMN1; SMN2USP2CYP1A2 | |
| SCHEMBL21440788 | 0.87 | ALDH1A1 (0.48) | TSHRKDM4ESMN1; SMN2USP2CYP1A2 | |
| SCHEMBL21769411 | 0.87 | FNTA (0.41) | TSHRKDM4ESMN1; SMN2LMNACYP2C9 | |
| SCHEMBL21769409 | 0.87 | KDM4E (0.40) | TSHRKDM4ESMN1; SMN2LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | ILK, LRRC47, RPL37 | TSHR 2468/4885KDM4E 3638/4885SMN1; SMN2 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.